Goldman Sachs
VTVT icon

Goldman Sachs’s vTv Therapeutics VTVT Stock Holding History

Goldman Sachs’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529K Buy
13,350
+7,819
+141% +$284K ﹤0.01% 5567
2025
Q4 		$221K Buy
+5,531
New +$154K ﹤0.01% 6003
2021
Q4 		– Sell
-603
Closed -$37K – 6730
2021
Q3 		$37K Sell
603
-224
-27% -$16.9K ﹤0.01% 6097
2021
Q2 		$75K Sell
827
-747
-47% -$75.7K ﹤0.01% 6014
2021
Q1 		$178K Buy
+1,574
New +$155K ﹤0.01% 5685
2020
Q3 		– Sell
-477
Closed -$43K – 5556
2020
Q2 		$43K Buy
477
+19
+4% +$1.88K ﹤0.01% 5075
2020
Q1 		$35K Buy
+458
New +$44K ﹤0.01% 5087
2019
Q4 		– Sell
-267
Closed -$17K – 5424
2019
Q3 		$17K Buy
+267
New +$15.1K ﹤0.01% 5115
2018
Q4 		– Sell
-374
Closed -$12K – 5708
2018
Q3 		$12K Sell
374
-764
-67% -$35.8K ﹤0.01% 5461
2018
Q2 		$70K Buy
+1,138
New +$84.1K ﹤0.01% 5286

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's VTVT Position: Q1 2026 in Review

Goldman Sachs increased its vTv Therapeutics (VTVT) stake by 141% in Q1 2026, buying an estimated $284K and bringing the position to 13,350 shares worth $529K. The position accounts for ﹤0.01% of the portfolio, ranked #5567.

Goldman Sachs first reported a position in VTVT in Q2 2018 and has held it in 10 quarters since. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • Goldman Sachs held 13,350 shares of vTv Therapeutics worth $529K as of Q1 2026.
  • Goldman Sachs bought 7,819 vTv Therapeutics shares in Q1 2026, an estimated $284K.
  • vTv Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5567 holding.
  • Goldman Sachs first reported a position in vTv Therapeutics in Q2 2018 and has held it in 10 quarters since.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.